DPA Microphones

DPA Microphones (originally Danish Professional Audio) is a Danish owned manufacturer of microphones and microphone solutions for professional and consumer markets. The company was founded in 1992 by two former employees from Brüel & Kjær. The company’s headquarters is located in Allerød in Denmark.

Awards:

1989: TEC Award – 4011 Cardioid Microphone

2002: TEC Award nominee: 4066 Cardioid Headset Microphone

2004: TEC Award nominee - 4088 Directional Headset Microphone

2006: WFX Best New Product Award - SMK4061 Stereo Microphone Kit With Miniature Microphones

2007: DPA Microphones received the prestigious award King Frederik IX award.

2009: The DPA d:vote™ 4099 instrument microphones received several awards (Audio Media Gear of the Year, TEC Award)

2010: PAR Excellence Award - Reference Standard

2010: Resolution Award - 5100 Mobile Surround Microphone

2010: TEC Award nominee - 5100 Mobile Surround Microphone

2011: Audio Media Gear of the Year - Reference Standard Microphone Series

2011: MIX Certified Hit - Reference Standard Microphone Series

DPA

DPA may refer to:

Organisations

Government and politics

DPA-713

DPA-713 or N,N-diethyl-2-(4-methoxyphenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-acetamide is a selective ligand for the translocator protein (TSPO).

The binding affinity of DPA-713 for TSPO is reported as K_i = 4.7 ± 0.2 nM.

DPA-713 has been radiolabelled with carbon-11 as a potential radiotracer for imaging the TSPO using positron emission tomography (PET). Radiation dosimetry and biodistribution of [¹¹C]DPA-713 have been assessed in healthy volunteers, indicating that [¹¹C]DPA-713 is a suitable radioatracer for imaging the TSPO in humans.

See also

References

DPA-714

DPA-714 or N,N-diethyl-2-[4-(2-fluoroethoxy)phenyl]-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-acetamide is a selective ligand for the translocator protein (TSPO) currently under evaluation for several clinical applications. For this reason, a practical, multigram synthetic route for its preparation has been described.

The binding affinity of DPA-714 for TSPO is reported as K_i = 7.0 ± 0.4 nM.

[¹⁸F]DPA-714 is currently under investigation as a potential radiopharmaceutical for imaging TSPO in living systems using positron emission tomography (PET). DPA-714, along with other members of the DPA class of TSPO ligands, has been shown to decrease microglial activation and increase neuronal survival in a quinolinic acid rat model of excitotoxic neurodegeneration, suggesting potential neuroprotective effects.

See also

References